Collegium Pharmaceutical Inc. (NASDAQ:COLL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “

Several other research analysts have also commented on COLL. Piper Jaffray Cos. set a $23.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, October 12th. Gabelli assumed coverage on Collegium Pharmaceutical in a research report on Tuesday, September 13th. They set a “buy” rating and a $25.00 price target for the company. Needham & Company LLC restated a “buy” rating and set a $30.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, September 14th. Finally, Jefferies Group restated a “buy” rating and set a $24.00 price target (down from $27.00) on shares of Collegium Pharmaceutical in a research report on Friday, November 11th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $27.00.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL) opened at 16.19 on Tuesday. Collegium Pharmaceutical has a 52 week low of $8.24 and a 52 week high of $30.58. The stock’s market capitalization is $379.82 million. The company’s 50-day moving average price is $16.93 and its 200 day moving average price is $14.15.

Several hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. boosted its stake in shares of Collegium Pharmaceutical by 8.9% in the second quarter. Franklin Resources Inc. now owns 903,602 shares of the specialty pharmaceutical company’s stock valued at $10,708,000 after buying an additional 74,003 shares during the last quarter. Alliancebernstein L.P. acquired a new stake in Collegium Pharmaceutical during the second quarter worth $122,000. BlackRock Institutional Trust Company N.A. boosted its stake in Collegium Pharmaceutical by 41.0% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 261,332 shares of the specialty pharmaceutical company’s stock worth $3,097,000 after buying an additional 75,984 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Collegium Pharmaceutical by 29.3% in the second quarter. BlackRock Fund Advisors now owns 650,474 shares of the specialty pharmaceutical company’s stock worth $7,708,000 after buying an additional 147,461 shares in the last quarter. Finally, BlackRock Investment Management LLC boosted its stake in Collegium Pharmaceutical by 97.1% in the second quarter. BlackRock Investment Management LLC now owns 51,546 shares of the specialty pharmaceutical company’s stock worth $611,000 after buying an additional 25,388 shares in the last quarter. Institutional investors and hedge funds own 49.08% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza), is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication.

5 Day Chart for NASDAQ:COLL

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.